← Back to Clinical Trials
Recruiting NCT07230262

NCT07230262 Trial Comparing Multiport RObotic and Laparoscopic Surgery for Elective Colorectal Resections in IBD Patients (ACRO-IBD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07230262
Status Recruiting
Phase
Sponsor Universitaire Ziekenhuizen KU Leuven
Condition IBD - Inflammatory Bowel Disease
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2025-10-01
Primary Completion 2028-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Robotic colorectal surgeryLaparoscopic colorectal surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2025-10-01 with a primary completion date of 2028-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to better understand whether robotic surgery leads to better outcomes than laparoscopy in terms of complications, recovery and quality of life.

Eligibility Criteria

Inclusion Criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. At least 18 years of age at the time of signing the Informed Consent Form (ICF) 3. Diagnosed with IBD and eligible for elective minimally invasive colorectal surgery, including: 1.4 Ileocecal/ileocolic resections 1.5 Segmental colectomies 1.6 Total colectomy 1.7 Proctocolectomy 1.8 Proctectomy 4. Procedures involving primary anastomosis or temporary or permanent stoma creation 5. Suitable for minimally invasive surgery Exclusion Criteria: 1. Non IBD patients 2. Urgent surgery (\<24 hours from hospital admission) 3. Not suitable for minimally invasive surgery 4. Ileoanal pouch construction

Contact & Investigator

Central Contact

Isabelle Terrasson

✉ isabelle.terrasson@uzleuven.be

📞 +3216340837

Principal Investigator

Gabriele Bislenghi, Professor

PRINCIPAL INVESTIGATOR

UZ Leuven

Frequently Asked Questions

Who can join the NCT07230262 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying IBD - Inflammatory Bowel Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07230262 currently recruiting?

Yes, NCT07230262 is actively recruiting participants. Contact the research team at isabelle.terrasson@uzleuven.be for enrollment information.

Where is the NCT07230262 trial being conducted?

This trial is being conducted at Leuven, Belgium.

Who is sponsoring the NCT07230262 clinical trial?

NCT07230262 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Gabriele Bislenghi, Professor at UZ Leuven. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology